Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Rocketing demand, legal disputes, and the future of weight loss were all spurred by a new class of anti-obesity medications.

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...

Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...

Investing.com - Eli Lilly's (NYSE: LLY) full-year profit forecast largely surpassed Wall Street expectations on Thursday, as ...

Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...